Metsera, Inc.
MTSR
주식 순위
#2571
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
주가
$70.50
마지막 동기화: 2025-11-14
시가총액
$7.33B
변동 (1일)
0.00%
변동 (1년)
33.60%
국가
US
거래 Metsera, Inc. (MTSR)
카테고리
Healthcare
Metsera, Inc. (MTSR)의 주가 이력
최고 종가: $72.34 (2025-11-01 기준)
최저 종가: $26.50 (2025-01-01 기준)
최저 종가: $26.50 (2025-01-01 기준)
Metsera, Inc.의 주가 이력 (2025 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | -10.54% |
| 2025 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $763.31 | 8.49% |
CH
|
